Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatitis B virus major surface antigen (HBsAg) is a key envelope glycoprotein found on the surface of the hepatitis B virus (HBV) and is the primary serological marker used to diagnose acute and chronic HBV infections. HBsAg plays a critical role in the viral life cycle, facilitating viral attachment and entry into host hepatocytes by interacting with the sodium taurocholate co-transporting polypeptide (NTCP) receptor. In chronic HBV infection, the virus produces and secretes vast quantities of non-infectious subviral particles composed of HBsAg, which act as an immunological decoy to exhaust and suppress the host's immune response, preventing viral clearance. Consequently, reducing HBsAg levels is considered a prerequisite for achieving a 'functional cure,' defined as sustained undetectable HBV DNA and HBsAg loss after stopping therapy. Therapeutic strategies targeting HBsAg include antisense oligonucleotides (such as the FDA-approved bepirovirsen) and small interfering RNAs (siRNAs like elebsiran and xalnesiran) that degrade viral transcripts to suppress HBsAg production. Additionally, monoclonal antibodies (such as tobevibart) and hepatitis B immune globulins directly bind and neutralize circulating HBsAg, blocking viral entry and promoting immune-mediated clearance of viral particles.
Antisense oligonucleotides (e.g., bepirovirsen) and small interfering RNAs (siRNAs; e.g., elebsiran, xalnesiran) target and degrade HBV RNA transcripts to inhibit HBsAg translation. Monoclonal antibodies (e.g., tobevibart) and immune globulins directly bind to the antigenic loop of HBsAg, neutralizing viral infectivity, blocking NTCP-mediated entry into hepatocytes, and promoting clearance of viral particles. Nucleic acid polymers (e.g., REP 2139) prevent the assembly and secretion of HBsAg-containing subviral particles.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis B virus major surface antigen (HBsAg).